JFS Wealth Advisors’s ADMA Biologics ADMA Stock Holding History

JFS Wealth Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$310	Sell	37 -41	-53%	-$374	﹤0.01%	2056
2026 Q1	$703	Buy	78 +6	+8%	+$95	﹤0.01%	1730
2025 Q4	$1.31K	Buy	72 +19	+36%	+$320	﹤0.01%	1657
2025 Q3	$777	Sell	53 -38	-42%	-$651	﹤0.01%	1677
2025 Q2	$1.66K	Buy	91 +18	+25%	+$367	﹤0.01%	1441
2025 Q1	$1.45K	Hold	73	–	–	﹤0.01%	1573
2024 Q4	$1.25K	Buy	73 +19	+35%	+$357	﹤0.01%	1630
2024 Q3	$1.08K	Buy	+54	New	+$840	﹤0.01%	1679

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JFS Wealth Advisors's ADMA Position: Q2 2026 in Review

JFS Wealth Advisors reduced its ADMA Biologics (ADMA) stake by 53% in Q2 2026, selling an estimated $374 and leaving 37 shares worth $310. The position accounts for ﹤0.01% of the portfolio, ranked #2056.

JFS Wealth Advisors first reported a position in ADMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.66K in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

JFS Wealth Advisors held 37 shares of ADMA Biologics worth $310 as of Q2 2026.
JFS Wealth Advisors sold 41 ADMA Biologics shares in Q2 2026, an estimated $374.
ADMA Biologics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #2056 holding.
JFS Wealth Advisors first reported a position in ADMA Biologics in Q3 2024 and has held it in 8 quarters since.
JFS Wealth Advisors's ADMA Biologics position peaked at $1.66K in Q2 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.